Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
KUMAR, AMRENDRA
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD	Active, not recruiting	3	806	Europe, Canada, Japan, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD	Pulmonary Disease, Chronic Obstructive	08/24	08/24
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25
NCT05107362: Clinical Performance of the Checkable Medical At-Home Strep A Test	Completed	N/A	1347	US	untrained lay user performs investigational diagnostic test	Checkable Medical Inc, Curebase Inc.	Streptococcus Pyogenes Infection, Pharyngitis, Respiratory Tract Infections	07/23	07/23